recently showed that HDAC3-selective inhibitors have a dual effect by reversing CREBBP-mutant aberrant epigenetic programming limiting lymphoma growth inhibition while restoring antitumor immunity, notably antigen presenting-genes (96). This evidence concerns the gene HDAC3 and lymphoma.